12 results about "Leonurine" patented technology

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

The invention relates to the field of modern pharmacy of traditional Chinese medicines, and discloses application of leonurine in preparation of antibacterial products. According to the invention, the in-vitro antibacterial activity of leonurine is detected by an agar dilution method and a broth trace dilution method. The result shows that the leonurine can inhibit the proliferation of a staphylococcus aureus standard strain, and also has an inhibiting effect on most of methicillin-sensitive staphylococcus aureus, methicillin-resistant staphylococcus aureus and methicillin-resistant coagulase-negative staphylococcus which are obtained by clinical separation; meanwhile, the leonurine can inhibit proliferation of a malassezia standard strain and a clinical isolated strain, also has an inhibiting effect on most of ketoconazole drug-resistant candida and ketoconazole dose dependence-sensitive candida obtained through clinical isolation, and can be used for preparing antibacterial pharmaceutical compositions and skin care products.

The invention discloses a leonurine hydrochloride and ursolic acid self-assembled nano preparation and application thereof in preparation of a medicine for treating acute lung injury. The invention provides a leonurine and ursolic acid self-assembled nano-preparation. The leonurine and ursolic acid self-assembled nano-preparation is obtained by self-assembling leonurine pharmaceutically acceptable salts and ursolic acid, wherein the amounts of the leonurine pharmaceutically acceptable salts and the ursolic acid are equal. The self-assembled nanoparticles have an obvious anti-lung inflammation effect, and the anti-inflammatory effect is obviously superior to that of a composition of the leonurine pharmaceutically acceptable salt and ursolic acid with the same dosage. Therefore, the leonurine and ursolic acid self-assembled nano preparation provided by the invention has the prospect of being developed into the medicine for treating the acute lung injury.

The invention relates to the technical field of functional antioxidants, in particular to a magnesium-based multi-level composite functional layer preparation method and application thereof.The magnesium-based multi-level composite functional layer preparation method comprises the steps that S1, superfine brucite is added with a tetrasilanol-water mixed solution for spraying, stirring is conducted at the temperature of 25-50 DEG C, then the temperature is increased to 80-100 DEG C for reaction, cooling and drying are conducted, silane hybridized brucite is obtained, and the molar mass ratio of silane to brucite is 0.5-2 mol: 10 kg; s2, adding a leonurine alcohol and water mixed solution into the silane hybridized brucite, spraying, dedusting and drying to obtain leonurus alkalized brucite; s3, adding piperlonguminol and water mixed solution into the motherwort alkalized brucite, spraying, stirring at 40-60 DEG C, heating to 100-120 DEG C, reacting, dedusting and drying to obtain cross-linked powder; and S4, adding a mixed solution of nano silicon dioxide and gamma-aminopropyltriethoxysilane into the cross-linked powder, stirring at 30-50 DEG C, and drying to obtain the composite functional layer. The composite functional layer prepared by the method can be used for visually monitoring the viscosity of the flame-retardant spray, has good flame-retardant synergism, is stably dispersed in the spray, is simple and environment-friendly in preparation process, is suitable for industrial production, and is suitable for various flame-retardant spray types.

The invention relates to an alkaloid liposome, a preparation process thereof and an application of the alkaloid liposome in an external preparation, and belongs to the technical field of external preparations. The technical problem to be solved is to provide an alkaloid liposome technology which is higher in stability, safe and non-irritating. According to the scheme, the alkaloid liposome technology is characterized in that raw materials comprise alkaloid, hydrogenated lecithin, grease, polyhydric alcohols and water; the alkaloid is selected from at least three of piperine, tetrahydropiperine, tetrahydropalmatine, dihydrooat alkaloid D, caffeine and leonurine; the hydrogenated lecithin is selected from at least one of PHOSPHOLIPON80H or PhoslipTM HPC (Hydroxyethyl Propyl Phosphatidylcholine). The liposome is good in stability and low in irritation, and has the effects of promoting local tissue microcirculation, reducing choked flow rate, increasing local body temperature, enhancing tissue metabolism and improving local inflammation when being externally applied to skin.

The invention belongs to the technical field of biological medicines, and particularly relates to a drug-loaded nano-micelle as well as a preparation method and application thereof. According to the invention, bromoalkanes with different chain lengths are introduced to a leonurine phenolic hydroxyl group by adopting a total synthesis method to prepare a leonurine derivative, and the drug-loaded nano-micelle is prepared by applying triptolide (TP) and the leonurine derivative. The embodiment of the invention verifies that the drug-loaded nano-micelle can reduce in-vivo and in-vitro toxicity caused by triptolide and improve the treatment effect on a mouse arthritis model induced by type II collagen. The novel triptolide compatible medicine prepared by the invention is small in toxic and side effects and has a good curative effect on rheumatoid arthritis.

The application relates to the technical field of cell protection, and provides a cell protection solution, a protection method and application. The cell protection solution comprises leonurine, human serum albumin and physiological saline. The cell protection method comprises the following steps: S1, adding the human serum albumin into physiological saline to prepare a cell preservation solution; S2, adding the leonurine into the cell preservation solution to prepare a cell protection solution; and S3, resuspending and preserving collected mesenchymal stem cells or immune cells by using the cell protection solution. The cell protection solution is applied to mesenchymal stem cells and immune cells. The cell protection solution, the protection method and the application can maintain cell activity after mesenchymal stem cells and immune cells are prepared into cell preparations and have no toxic side effects on the cells.

The invention discloses an exosome preparation for treating premature ovarian failure, and belongs to the technical field of biology. And adding leonurine and estradiol into the umbilical cord mesenchymal stem cell culture solution, and co-culturing to prepare the exosome preparation for treating premature ovarian failure. The conventional exosome and the leonurine and estradiol co-cultured exosome with the same dosage can weaken the inhibition effect of the 4-OHCP on the KGN cell activity, and the leonurine and estradiol co-cultured exosome has a better human ovarian granular cell damage repair effect than the conventional exosome. When the leonurine and estradiol co-cultured exosome is used for treating a rat with premature ovarian failure, inflammatory cell infiltration in ovarian tissue interstitial substances is improved, follicle granular cell layers are increased, follicles in the growing period are increased, and mature follicles develop. Compared with a premature ovarian failure model group, the leonurine and estradiol co-cultured exosome group has the advantages that the serum FSH and LH levels of rats are reduced, the AMH level is increased, and the treatment effect on the premature ovarian failure rats is superior to that of a conventional exosome group.

The invention belongs to the technical field of traditional Chinese medicine quality control methods, and relates to a quality control method for traditional Chinese medicine motherwort in different harvesting periods. The quality control method comprises the following specific steps: preparation of a test solution, preparation of a mixed reference solution and a determination method, wherein a chromatographic column adopts a C18 column; a mobile phase is a methanol-10 [mu] mol / L ammonium acetate aqueous solution, gradient elution is carried out for 0-20 min, and methanol is 45%-100%; the flow velocity is 1.0 mL / min; the detection wavelength is as follows: the wavelength of quercetin, kaempferol and luteolin is 254 nm, and the wavelength of leonurine is 280 nm; the column temperature is 30 DEG C; the sample size is 5 microliters. According to the method disclosed by the invention, drug effects are taken as guidance, the screened chemical components quercetin, kaempferol, luteolin and leonurine not only can reflect the overall drug effects of medicinal materials, but also have part specificity, so that not only can the problem of disordered composition of medicinal parts caused by nonstandard harvesting time be solved, but also accurate association of'component-drug effects-quality 'can be realized, and the method is suitable for popularization and application. The method has important theoretical value and practical significance for guaranteeing the quality stability and the clinical curative effect reliability of the motherwort herb.

The application discloses an alkaloid liposome and a preparation process and application thereof in external preparations, and belongs to the technical field of external preparations. The technical problem to be solved is to provide an alkaloid liposome technology with higher stability and safety and no irritation. The scheme points are that raw materials include alkaloids, hydrogenated lecithin, oil, polyhydric alcohol and water; the alkaloids are selected from at least three kinds of piperine, tetrahydropiperine, fumarine, dihydroavenanthramide D, caffeine and leonuride; the hydrogenated lecithin is selected from at least one of PHOSPHOLIPON 80H or Phoslip HPC. The liposome has good stability and low irritation, and has the effects of promoting local tissue microcirculation, reducing resistance, improving local inflammation, improving local body temperature, enhancing tissue metabolism and the like when being used externally on the skin.

This invention discloses a novel use of M1 (Leonurus glucuronide, ZYZ-488), the main glucuronide conjugate metabolite of leonurine, in the preparation of drugs for preventing and treating endometrial damage and / or intrauterine adhesions caused by mechanical curettage. M1 promotes endometrial regeneration, remodeling, and restoration of endocrine function by increasing serum prostaglandin E2 (PGE2) and / or leukemia inhibitory factor (LIF) levels, while simultaneously restoring serum estradiol (E2) and / or progesterone (P4) levels to normal physiological ranges. It also significantly increases endometrial thickness, the number and regular arrangement of glands, improves stroma density, and enhances tissue morphology remodeling. This invention overcomes the technical bias that Phase II metabolites are typically considered inactivated forms, as well as the thrombotic risks of existing estrogen drugs (EVs) and the strong irritation and insufficient long-term protection of the parent compound SCM-198. It provides a safe, mild, stable, and suitable oral formulation for long-term use, offering a novel and effective drug option for the prevention and treatment of clinical endometrial damage and intrauterine adhesions.

The application provides application of UGT5 genes and SCPL12 genes in production of agrostemma herb base in hairy roots. The application is realized by designing primer compositions to amplify the UGT5 genes and the SCPL12 genes, constructing a recombination carrier by using a Gateway technology, transforming the recombination carrier into Agrobacterium rhizogenes to obtain an Agrobacterium rhizogenes strain containing the UGT5 and the SCPL12, infecting leaves of Leonurus japonicus by using the Agrobacterium rhizogenes strain, culturing to obtain transgenic Leonurus japonicus hairy roots, and further producing the agrostemma herb base in the hairy roots. The content of the agrostemma herb base in the hairy roots of Leonurus japonicus obtained by using the Agrobacterium rhizogenes mediation and simultaneously overexpressing the UGT5 and the SCPL12 is higher than that of a control group. The method lays a foundation for production of the agrostemma herb base in transgenic plant cells.